CAPSID INHIBITORS
| Mutations associated with resistance | Mutations associated with « possible resistance » | |
| LEN |  L56I [1] M66I [1] Q67H [1] K70N/R/S [1, 2] N74D/S [1] T107N [1] |
LEN : lenacapavir
1/ Yant SR, Mulato A, Hansen D et al. In vitro resistance profile of GS-6207, a first-in-class picomolar HIV capsid inhibitor in clinical development as a novel long-acting antiretroviral agent. Tenth IAS Conference on HIV Science, Mexico City, Mexico, 2019. Poster TUPEA075.
2/ Molina JM Segal-Maurer S, Stellbrink HJ et al. Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) .IAS 2021,abstract OALX01LB02.